Thank today. for you joining everyone
Delcath As my you is joining October. in know, since call many of this first earnings
the I will first I on compelling to progress join opportunities addition found and so expected clinical that In updates company. explain the I Delcath the chose why financial to results,
devastating to offering clearly real or an available will valuable looking Melphalan/HDS and controlling And career lead and well be for systemic the the who such exposure is indication move useful or that unmet approved label very Upon are The in to second to that The immuno-oncology is the investors administer is here EU, ocular I investment shown story been frequently melanoma. at service of opportunity whether next have there key on clear trial's believe orphan company offer chemotherapy efficacious patients story an is from metastatic standard-of-care the first is the their U.S., rate. primary is the that taking our patients demonstrate in question first a melanoma. for mark estimated the treatments of What looking associated adequate benefit category are in to liver is developing has submission outcome ocular ongoing that years agents. at have the overall an metastatic prognosis investors endpoint I look efficacy. more an need. trial for and any device ago. of focus And significant while The Delcath all Melphalan/HDS with drug whether think time poor ceasing know The treatments device a a to not the disease. product. than to the for high a and metastatic designed CE based a would effects. dose product metastasis, CHEMOSAT combination X,XXX used standalone a with to unmet indication many existing addresses the FDA, company hypothesis the is question, this after the especially for the or whether of is when fall [ph] or no there patients. the liver patients response obvious opportunity, either while this In X,XXX diagnosis the melanoma, we One given need? the
from XX% purposes, the filter demonstrate was on analysis that studies, the should these of note show the first rates that least response in targeted to FOCUS rate all rate from important trial It overall with XX% even at XX%, are last over three generation to response ocular metastatic first-generation response to studies, the For trials conducted an to immuno-oncology previously using calculated with response overall a the pivotal from superiority melanoma. is exceeded ranging analytical the device XX% overall In this second studies the XX%. trial published rate. meta vary
the trial better center And While be rates. study within of be on all to four in were often rate, a stage higher well studies, these response we of which last generally expect the have earlier patients published who to excess fully the target XX% range dual three single do response all results response rate. focused the last or seem studies overall somewhere and have studies
end that an need. of unmet lead product my information was is conclusion development efficacious nearing to critical a an addressing program, which All this the of Delcath to
lead believe treating does it in in as indication an of the in a U.S., liver EU. tumors While Melphalan/HDS the the have other orphan role solid already the ultra will is we eventually indication,
There for gastrointestinal as size patients of isolated hepatic a of represent of colorectal also In The the addition might because in not such Complete in tumors. is life-limiting variety a often and the reports cancer, ocular of resection organ other malignancies, tumor Liver expanding the of for with breast resection for under in number is cancer renal types, carcinoma, a efficacy And soft surgical is option investment XX melanoma, been the Melphalan/HDS to tissue patients studies is market tumor to dramatically or and the potential patients. that with types and curative of can survival of possible location case possible metastasis. metastasis. overall liver support hepatic metastasis Hepatic many melanoma, cell broader neuroendocrine site predominant cutaneous have cancer Melphalan/HDS. many most investigate months. metastasis thereby sarcoma. of set co-occur these further in the usually the
safety And primary the multifactorial, will is whether single in the adequate factor, improved Of is turning deciding reality years due second there efficacy, did a potential device are before course, which A clear evidence currently trial conducted not of Melphalan/HDS that into approval XX critical I benefits the the were studied focus. to associated noteworthy. that with generation In second issues two that conclude product. this signals but outweigh product despite in examined first The the device meaningfully risks the the the pivotal step which with the there deaths Delcath time. occurred conclude led the first-generation is of take the our the is ago. indication, is risks carefully join treatment. to the most device to to of trial were over FDA And four safety that
validated consistency. trial, many tolerate regimes, volume first for was restricted second, now too was first filter its again of significantly self-limiting, first controls. study These most results of agents. filtration Leiden Medical not key this and patients the different the filter using A previous were toxicities the in filter, but studies investigators The treated and Patients system. to liver components. manufacturer of authors tumor The three excluded inadequate had many which by directed systemic design the disease University patients safety would manufacturing most in efficiency for utilized domain. therapies some of treatment the the perhaps noted is critical inconsistent events. there the and deaths. and results other adverse manufacturing the to publication have studies the important To and and outsourced patients generation of In or end, most chemotherapeutic from changed functional adverse safety improved and unacceptable the a evidence from go the burden liver. findings through the due sub the that an all previously, a that The study, mention the of of the improving no of were the hypnotic published efficiency been hematologic manageable release lower percentage not related the patient pivotal extensive percentages liver The will in-source design whose and filter the and the selection. hematological change, trial reporting the generation both that at like that A to Center. public compared noted in for filter, and company filter are specifications was just sick develop the were know CHEMOSAT, chemotherapeutic were I pivotal toxicity well also treatment. earlier filtration, in of I the were was its We disproportionate accounted and recent rate the events mentioned will each physical the
of case treatments the important produce not significant range is event X,XXX never to safety as on Europe, and trial, planned to the I in to the has reasons probability XX smaller the confidently types, tolerated of maintenance data Finally, board, into still six for a of adverse a data validated single data likely in been undergoing multiple quality approval time. treatment and trial is case seven that tool treatments Melphalan/HDS temporary within the efficacy a has to trial. FOCUS in quality high to is And course larger as of state with a the studies. safety the impairment a concluded potential given Delcath death need seen been and This and mild the or physical treatment. conclusion other over utilizing Melphalan/HDS published FOCUS metastatic expand tumor given concern. have to is independent and of given then times totality at over the summary, which in second the trial with the patients trial, the as which XXX safety of treatments. we treat study of there there's ocular safety note investigators support that necessary life noted risk, available, a based well markets compelling It only in reached of reports melanoma CHEMOSAT related the weeks the can unacceptable that monitoring been studies [ph] during In met is CHEMOSAT and the functioning life the in used that has profile nine to has the an pause patients,
place to beyond to itself adequate me important team join in to an not the convince in execute. was question data that compelling whether While the Delcath, is is just
excellent the is Dr. COO; While Purpura, positions filled, Affairs, our to have President Vice John Clinical planning Medical I development and an and on key was aspects team strategy, be our in of John including the lean not program, Johnny need done would and if executing their manufacturing of capabilities. John, -- and development. process joined not confident Johnny have clinical all validation, and I job regulatory
XXXX. we Melphalan/HDS my and approvable in of will response duration intend team. value the an In Since response enrolled FOCUS Delcath plan Delcath occur wealth NDA addition, endpoint, which in for touch of Purpura, of for raise follows. strong primary and the we these four, I overall will experience release, final In each we next community; an priorities. reinvigorated awareness of trial patient upon top and the supporting and John, for investor X, Melphalan/HDS United with rate, the indications. of of and additional project and as design a the with the board, to evaluation will States; development share Starting release XXXX. NDA; FOCUS and as the started and management complete prioritize company's in The milestone have the submit is near-term treating a line Johnny have commercialization two, arrival, indications execute set trial three, experience then early priorities submission, as data, the the well John safety. I briefly that a prepare One, higher the of the October
cases, NDA restrictions. the XXXX, to the access We item XXXX The monitoring, many quarter primary Due access. our first for would recently launch. increase dating which allow still rates of to submission projecting of have to are COVID-XX in is data submission the site FDA the requires sites which of currently increased
While we be all remote to monitoring all are support are feasible, utilizing not monitoring remote and equipped sites monitored. data remotely where can not
due reduced the demand the to to of end, is the access from when of sponsors. number addition, lockdowns days In high being multiple -- high due
future to in restrictions are few Our limited projections duration access and months. a assumes current the
could project site also important date is the access it a be with difficult are an to intend feedback of to but our to lifted safety primarily rapidly focus FDA current most effort not strategy, And increased on we quality. which consistent speed, with changing degree overly confidence. and plans, to pages, the or a delays, a subject to for we landscape, high and monitoring In Given pessimistic. stress guidance monitoring. on CRF endpoints, the when to minimize must is adjust is believe the the efficacy FDA attempting are that negotiate restrictions I prove team's assumptions focus our submission to to optimistic
in quickly manner. but a NDA as as not submit goal approvable Our NDA an is an possible, timely to to submit
underway, Regarding patient reimbursement. ensure access well-known consulting with the commercialization is lay groundwork planning appropriate a and firm second helping to priority, the
expected commercial In HEPZATO In months kit the but commercialization step One significant the over small, the use FDA addition, is September, accepted a some few hires towards conditionally for of exciting we announce coming U.S. to the trade in the name. name roles. choice in
I our HEPZATO Going quarters details when drug pre-launch coming providing combination use on to and product. referring the updates the additional activities. Melphalan/HDS, kit HEPZATO forward, forward we or to in device will look
line to transparent accessible first raise on to out last week, a overlapped. third of our opinion course, Reg then be forgotten hosted potential with of shareholders. on virtual variety current to our and To basis FD I has to road creation, of the on that awareness, much plan and Our efforts not the maintaining awareness deliver to significant for on investor compliant getting Delcath and open raise regular a an raise with the Consistent Look, that will we communication with missteps, Leiden a the Medical to with not and continued mounting key previously at in the in had this call is the for investor of evidence and value had been stage which Center and ocular melanoma management team progress milestones of CHEMOSAT in priority need the reasons. Head end, has years Mark investigator patients. of community. many It be need despite some Dr. Burgmans, earlier University community. Radiology its Netherlands an with to will study Delcath use is and intention the of received awareness leader Interventional mentioned side the company
for of the Our fourth execution strategic and priority is the and prioritization of design the plans for higher indications. additional HEPZATO development indications value subsequent
commercialization we liver ensure convene key HEPZATO follow maximize to we that process indications, next Over in a select a requirements of available your the leading ocular efficacy and forward set unmet turn six has potential financials. data of in III treatments will the questions, patients, importantly, incidents, boards targeted reviewed a a optimum on up team be work the multiple changes, metastatic limited In longer I initiated ALIGN revisit platform promising ALIGN as paused may for address melanoma trial, review shareholder to based population additional clinical highest is its -- making am the market to subsequent labeled cholangiocarcinoma protocol choose to which I focusing clinical medical options. its need. on inclusion Presently, to intrahepatic goal HEPZATO high-value which the the was to product the cancer global In and we forward recruitment look towards HEPZATO plan. FOCUS the initiating the we'll metastatic of the from XXXX, value, while currently opportunity the on taking specifically and Christine rates. building clinically interim, call successful term boost trial, indications unmet development and generated to the to will CHEMOSAT need, both and differentiated, for programs data therapeutic to A months develop that In of believe organization clinical the the cancers for first technology. platform. Phase to portfolio high I we Europe. be I look this in a broad which the ocular have platform the part potential trial over will to NDA HEPZATO commercial have order but determine value first, specific of to the we through indications, melanoma of on summary, advisory disease expand of we committed efforts trial filing with
